EA020464B9 - Отдельные вариабельные домены антител против сывороточного альбумина - Google Patents
Отдельные вариабельные домены антител против сывороточного альбуминаInfo
- Publication number
- EA020464B9 EA020464B9 EA200900955A EA200900955A EA020464B9 EA 020464 B9 EA020464 B9 EA 020464B9 EA 200900955 A EA200900955 A EA 200900955A EA 200900955 A EA200900955 A EA 200900955A EA 020464 B9 EA020464 B9 EA 020464B9
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- serum albumin
- variable domains
- single variable
- antibody single
- against serum
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Согласно изобретению предложен лиганд с двойной специфичностью, содержащий первый вариабельный домен иммуноглобулина, обладающий первой специфичностью связывания, и комплементарный или некомплементарный вариабельный домен иммуноглобулина, обладающий второй специфичностью связывания.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/704,832 US9321832B2 (en) | 2002-06-28 | 2007-02-08 | Ligand |
PCT/GB2008/000453 WO2008096158A2 (en) | 2007-02-08 | 2008-02-08 | Antibody single variable domains against serum albumin |
Publications (3)
Publication Number | Publication Date |
---|---|
EA200900955A1 EA200900955A1 (ru) | 2010-04-30 |
EA020464B1 EA020464B1 (ru) | 2014-11-28 |
EA020464B9 true EA020464B9 (ru) | 2015-10-30 |
Family
ID=39518148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200900955A EA020464B9 (ru) | 2007-02-08 | 2008-02-08 | Отдельные вариабельные домены антител против сывороточного альбумина |
Country Status (16)
Country | Link |
---|---|
US (2) | US9321832B2 (ru) |
EP (4) | EP2559702B1 (ru) |
JP (2) | JP5562650B2 (ru) |
KR (2) | KR20090114445A (ru) |
CN (1) | CN101965364A (ru) |
AR (1) | AR065260A1 (ru) |
AU (1) | AU2008212682B2 (ru) |
BR (1) | BRPI0807480A2 (ru) |
CA (1) | CA2677069A1 (ru) |
CL (1) | CL2008000423A1 (ru) |
EA (1) | EA020464B9 (ru) |
ES (2) | ES2629353T3 (ru) |
MX (1) | MX2009008490A (ru) |
SG (1) | SG185869A1 (ru) |
TW (1) | TW200848427A (ru) |
WO (1) | WO2008096158A2 (ru) |
Families Citing this family (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110020345A1 (en) * | 2008-03-31 | 2011-01-27 | Christopher Herring | Drug fusions and conjugates |
CN102076355B (zh) | 2008-04-29 | 2014-05-07 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
KR20110016958A (ko) | 2008-06-03 | 2011-02-18 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
RU2010153578A (ru) | 2008-06-03 | 2012-07-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двойными вариабельными доменами и их применение |
CN102149825B (zh) | 2008-07-08 | 2015-07-22 | Abbvie公司 | ***素e2双重可变结构域免疫球蛋白及其用途 |
EP2337798A4 (en) * | 2008-10-14 | 2012-10-24 | Ca Nat Research Council | BSA-SPECIFIC ANTIBODIES |
EP2364326B1 (en) | 2008-12-05 | 2018-07-04 | Glaxo Group Limited | Methods for selecting protease resistant polypeptides |
KR101820968B1 (ko) | 2009-02-19 | 2018-01-23 | 글락소 그룹 리미티드 | 개선된 항-혈청 알부민 결합 변이체 |
KR20110119806A (ko) * | 2009-02-19 | 2011-11-02 | 글락소 그룹 리미티드 | 개선된 항tnfr1 폴리펩티드,항체 가변 도메인 및 길항제 |
EP3656788A3 (en) * | 2009-02-19 | 2020-07-29 | Glaxo Group Limited | Improved anti-serum albumin binding variants |
CA2756853A1 (en) * | 2009-03-27 | 2010-09-30 | Christopher Herring | Drug fusions and conjugates |
US20120058116A1 (en) | 2009-04-24 | 2012-03-08 | Andrew Beaton | Fgfr1c antibody combinations |
WO2011008814A2 (en) | 2009-07-14 | 2011-01-20 | Immune Tolerance Institute, Inc., A California Not-For-Profit Corporation | Multiplexed measurement of exogenous and endogenous dna |
CA2768460A1 (en) | 2009-07-16 | 2011-01-20 | Glaxo Group Limited | Antagonists, uses & methods for partially inhibiting tnfr1 |
EP2454285A2 (en) * | 2009-07-16 | 2012-05-23 | Glaxo Group Limited | Improved anti-serum albumin binding single variable domains |
CA2768981A1 (en) | 2009-07-29 | 2011-02-03 | Rudolf Maria De Wildt | Ligands that bind tgf-beta receptor rii |
RU2012112550A (ru) * | 2009-09-01 | 2013-10-10 | Эбботт Лэборетриз | Иммуноглобулины с двумя вариабельными доменами и их применение |
JP2013506628A (ja) | 2009-09-30 | 2013-02-28 | グラクソ グループ リミテッド | 延長された半減期を有する薬物融合物及びコンジュゲート |
AR078651A1 (es) * | 2009-10-15 | 2011-11-23 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
EA022898B1 (ru) | 2009-10-27 | 2016-03-31 | Глаксо Груп Лимитед | Стабильные полипептиды, вариабельные домены антитела и антагонисты против tnfr1 |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
EP2523686A2 (en) | 2010-01-14 | 2012-11-21 | Glaxo Group Limited | Liver targeting domain antibodies |
US20130045895A1 (en) * | 2010-04-21 | 2013-02-21 | Rudolf Maria De Wildt | Binding domains |
CA2799633A1 (en) * | 2010-05-20 | 2011-11-24 | Elena De Angelis | Improved anti-serum albumin binding variants |
EP2571898B1 (en) * | 2010-05-21 | 2021-07-21 | The United States of America, as represented by The Secretary, Department of Health and Human Services | High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins |
CN103124788B (zh) | 2010-05-21 | 2016-01-13 | 梅里麦克制药股份有限公司 | 双特异性融合蛋白 |
MX341579B (es) | 2010-08-03 | 2016-08-25 | Abbvie Inc * | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
EP2603522A1 (en) * | 2010-08-13 | 2013-06-19 | GlaxoSmithKline Intellectual Property Development Limited | Improved anti-serum albumin binding variants |
BR112013003899A2 (pt) * | 2010-08-20 | 2016-06-07 | Glaxosmithkline Ip Dev Ltd | domínio variável único da imunoglobina anti-albumina sérica (sa), ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, método de tratar ou previnir uma doença ou distúrbio em um paciente |
TW201211252A (en) | 2010-08-26 | 2012-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
WO2012042026A1 (en) | 2010-09-30 | 2012-04-05 | Ablynx Nv | Biological materials related to c-met |
CN113278077A (zh) | 2010-11-26 | 2021-08-20 | 分子组合公司 | 设计的与血清白蛋白结合的重复蛋白 |
JP2014501515A (ja) | 2010-12-01 | 2014-01-23 | グラクソ グループ リミテッド | 改良された抗血清アルブミン結合単一可変ドメイン |
SG191762A1 (en) | 2011-01-06 | 2013-08-30 | Glaxo Group Ltd | Ligands that bind tgf-beta receptor ii |
EP2670778A1 (en) | 2011-02-02 | 2013-12-11 | Glaxo Group Limited | Novel antigen binding proteins |
WO2012136792A2 (en) | 2011-04-07 | 2012-10-11 | Glaxo Group Limited | Cck compositions |
WO2012136790A1 (en) | 2011-04-07 | 2012-10-11 | Glaxo Group Limited | Compositions comprising fusion proteins or conjugates with an improved half -life |
RS64179B1 (sr) | 2011-05-27 | 2023-05-31 | Hoffmann La Roche | Dvostruko ciljanje |
WO2012163521A1 (en) | 2011-05-27 | 2012-12-06 | Dutalys | Removal of monomeric targets |
JP6324887B2 (ja) | 2011-06-23 | 2018-05-16 | アブリンクス エン.ヴェー. | 血清アルブミンに結合するタンパク質 |
EP2974737A1 (en) * | 2011-06-23 | 2016-01-20 | Ablynx N.V. | Techniques for predicting, detecting and reducing a specific protein interference in assays involving immunoglobulin single variable domains |
KR102246924B1 (ko) | 2011-06-23 | 2021-04-30 | 아블린쓰 엔.브이. | 면역글로불린 단일 가변 도메인을 수반하는 어세이에서 비특이적 단백질 간섭을 예측하고 검출하고 감소시키는 기법 |
US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
SI2776466T1 (sl) | 2011-11-11 | 2017-12-29 | Ucb Biopharma Sprl | Protitelesa, ki se vežejo na albumin in njihovi vezavni fragmenti |
JP2015508994A (ja) | 2011-12-30 | 2015-03-26 | アッヴィ・インコーポレイテッド | Il−13および/またはil−17に対する二重可変ドメイン免疫グロブリン |
CN102661932B (zh) * | 2012-04-17 | 2014-07-23 | 王利兵 | 一种基于表面等离子共振技术的种质资源中特定dna序列鉴定方法 |
WO2013167883A1 (en) | 2012-05-07 | 2013-11-14 | The University Court Of The University Of Aberdeen | Single domain binding molecule |
EP2888279A1 (en) | 2012-08-22 | 2015-07-01 | Glaxo Group Limited | Anti lrp6 antibodies |
AU2013337775B2 (en) | 2012-11-01 | 2017-03-30 | Abbvie Inc. | Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof |
WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
TW201512219A (zh) | 2013-03-15 | 2015-04-01 | Abbvie Inc | 針對IL-1β及/或IL-17之雙特異性結合蛋白 |
HUE049957T2 (hu) | 2013-03-15 | 2020-11-30 | Glaxosmithkline Ip Dev Ltd | Lag-3 elleni kötõfehérjék |
CA2909921C (en) | 2013-04-23 | 2022-12-06 | The University Court Of The University Of Aberdeen | Synthetic library of specific binding molecules |
BR112016004355A2 (pt) * | 2013-08-30 | 2017-10-17 | Aprilbio Co Ltd | constructo de fusão de parte efetora de fab anti-soroalbumina e método de preparação do mesmo |
US9580758B2 (en) | 2013-11-12 | 2017-02-28 | Luc Montagnier | System and method for the detection and treatment of infection by a microbial agent associated with HIV infection |
CN113150117A (zh) * | 2014-03-20 | 2021-07-23 | 百时美施贵宝公司 | 新的结合血清白蛋白的纤连蛋白iii型结构域 |
HUE058008T2 (hu) | 2014-05-16 | 2022-06-28 | Ablynx Nv | Immunglobulin variábilis domének |
TW201629215A (zh) * | 2014-09-30 | 2016-08-16 | 拜耳保健有限責任公司 | 使用凝血酶之組成物及治療方法 |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
JP6979577B2 (ja) * | 2015-02-20 | 2021-12-15 | アミロニクス アクティエボラーグ | アルツハイマーaベータペプチド結合ポリペプチド |
CA2979602C (en) | 2015-04-02 | 2022-12-20 | Molecular Partners Ag | Designed ankyrin repeat domains with binding specificity for serum albumin |
MX2017014908A (es) | 2015-05-21 | 2018-08-15 | Harpoon Therapeutics Inc | Proteinas de union triespecificas y metodos de uso. |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
BR112018004181A2 (pt) | 2015-09-02 | 2018-09-25 | Immutep S.A.S. | anticorpos anti-lag-3 |
ES2781207T3 (es) | 2015-09-23 | 2020-08-31 | Bristol Myers Squibb Co | Dominios de fibronectina de tipo iii de unión a seroalbúmina con velocidad de disociación rápida |
CN108367048B (zh) | 2015-10-02 | 2022-08-12 | 银溪制药股份有限公司 | 用于组织修复的双特异性治疗性蛋白质 |
TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗lag3抗體及其用途 |
NO2768984T3 (ru) | 2015-11-12 | 2018-06-09 | ||
CN115925919A (zh) | 2015-11-13 | 2023-04-07 | 埃博灵克斯股份有限公司 | 改进的血清白蛋白结合免疫球蛋白可变结构域 |
CN108473565B (zh) | 2015-11-18 | 2022-05-27 | 默沙东公司 | Ctla4结合剂 |
AU2016357460B2 (en) | 2015-11-18 | 2023-07-27 | Ablynx Nv | Improved serum albumin binders |
JP6817302B2 (ja) | 2015-11-18 | 2021-01-20 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Pd1および/またはlag3結合性物質 |
JP6779997B2 (ja) | 2015-11-18 | 2020-11-04 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Pd1/ctla4結合性物質 |
AU2017222700B2 (en) * | 2016-02-26 | 2018-09-27 | Imunexus Therapeutics Limited | Multi-specific molecules |
CN108883181A (zh) | 2016-04-05 | 2018-11-23 | 葛兰素史密斯克莱知识产权发展有限公司 | 在免疫疗法中抑制TGFβ |
EP3448873B1 (en) * | 2016-04-25 | 2023-12-20 | Idea Orchard, LLC | Engineered fha domains |
KR102533456B1 (ko) | 2016-05-18 | 2023-05-17 | 모더나티엑스, 인크. | 릴랙신을 인코딩하는 폴리뉴클레오타이드 |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
JP7042467B2 (ja) | 2016-05-20 | 2022-03-28 | ハープーン セラピューティクス,インク. | 単鎖可変フラグメントcd3結合タンパク質 |
US10100106B2 (en) | 2016-05-20 | 2018-10-16 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
CA3044659A1 (en) | 2016-11-23 | 2018-05-31 | Harpoon Therapeutics, Inc. | Prostate specific membrane antigen binding protein |
US10844134B2 (en) | 2016-11-23 | 2020-11-24 | Harpoon Therapeutics, Inc. | PSMA targeting trispecific proteins and methods of use |
CN117164710A (zh) * | 2016-12-07 | 2023-12-05 | 埃博灵克斯股份有限公司 | 改进的血清白蛋白结合免疫球蛋白单可变结构域 |
WO2018134235A1 (en) | 2017-01-17 | 2018-07-26 | Ablynx Nv | Improved serum albumin binders |
IL305912A (en) | 2017-01-17 | 2023-11-01 | Ablynx Nv | Improved serum albumin binding agents |
MA47456A (fr) * | 2017-02-10 | 2019-12-18 | Regeneron Pharma | Anticorps anti-lag3 radiomarqués pour imagerie immuno-pet |
JP7200138B2 (ja) | 2017-02-16 | 2023-01-06 | ソネット バイオセラピューティクス,インコーポレイテッド | アルブミン結合ドメイン融合タンパク質 |
US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
JP6886854B2 (ja) * | 2017-04-13 | 2021-06-16 | シスメックス株式会社 | 被検物質の情報取得方法 |
KR20200026810A (ko) | 2017-05-12 | 2020-03-11 | 하푼 테라퓨틱스, 인크. | Msln 표적화 삼중 특이적 단백질 및 사용 방법 |
JP7090347B2 (ja) | 2017-05-12 | 2022-06-24 | ハープーン セラピューティクス,インク. | メソテリン結合タンパク質 |
MA49249A (fr) * | 2017-06-05 | 2021-04-14 | Numab Therapeutics AG | Nouveaux anticorps anti-hsa |
CN111108126B (zh) * | 2017-07-19 | 2024-04-26 | 非营利性组织佛兰芒综合大学生物技术研究所 | 血清白蛋白结合剂 |
EP3470426A1 (en) | 2017-10-10 | 2019-04-17 | Numab Therapeutics AG | Multispecific antibody |
US20230192897A1 (en) | 2017-10-10 | 2023-06-22 | Numab Therapeutics AG | Multispecific antibody |
JP7084990B2 (ja) | 2017-10-13 | 2022-06-15 | ハープーン セラピューティクス,インク. | 三重特異性タンパク質と使用方法 |
BR112020007249B1 (pt) | 2017-10-13 | 2022-11-22 | Harpoon Therapeutics, Inc | Roteína de ligação a antígeno de maturação de célula b, proteína de ligação multiespecífica e uso das referidas proteínas |
CA3102823A1 (en) | 2018-06-22 | 2019-12-26 | Cugene Inc. | Cytokine-based bioactivatable drugs and methods of uses thereof |
EP3844181A1 (en) | 2018-08-30 | 2021-07-07 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
EP3843788A1 (en) | 2018-08-30 | 2021-07-07 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
JP7449292B2 (ja) | 2018-08-30 | 2024-03-13 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 加齢関連障害の治療法 |
WO2020069028A1 (en) | 2018-09-25 | 2020-04-02 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
GB201818460D0 (en) * | 2018-11-13 | 2018-12-26 | Crescendo Biologics Ltd | Single domain antibodies that bind human serum albumin |
CN111423509B (zh) * | 2019-01-10 | 2021-07-09 | 瑞阳(苏州)生物科技有限公司 | 抗hsa单域抗体及其融合蛋白的亲和层析纯化方法 |
EP3987010A1 (en) | 2019-06-21 | 2022-04-27 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
EP3816185A1 (en) | 2019-11-04 | 2021-05-05 | Numab Therapeutics AG | Multispecific antibody directed against pd-l1 and a tumor-associated antigen |
GB201919061D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibody |
CA3170833A1 (en) | 2020-02-21 | 2021-08-26 | Harpoon Therapeutics, Inc. | Flt3 binding proteins and methods of use |
EP4133084A1 (en) | 2020-04-09 | 2023-02-15 | Autolus Limited | Polypeptide |
GB202007441D0 (en) | 2020-05-19 | 2020-07-01 | Autolus Ltd | Polypeptide |
EP3915580A1 (en) | 2020-05-29 | 2021-12-01 | Numab Therapeutics AG | Multispecific antibody |
US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
EP3988568A1 (en) | 2020-10-21 | 2022-04-27 | Numab Therapeutics AG | Combination treatment |
WO2022122654A1 (en) | 2020-12-07 | 2022-06-16 | UCB Biopharma SRL | Multi-specific antibodies and antibody combinations |
CA3208781A1 (en) | 2021-02-02 | 2022-08-11 | Bithi CHATTERJEE | Multispecific antibodies having specificity for ror1 and cd3 |
EP4183800A1 (en) | 2021-11-19 | 2023-05-24 | Medizinische Hochschule Hannover | Novel sars-cov-2 neutralizing antibodies |
WO2024038095A1 (en) | 2022-08-16 | 2024-02-22 | Iome Bio | NOVEL ANTI-RGMb ANTIBODIES |
WO2024084203A1 (en) * | 2022-10-18 | 2024-04-25 | Isogenica Limited | Single domain antibodies binding to albumin |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004003019A2 (en) * | 2002-06-28 | 2004-01-08 | Domantis Limited | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
WO2005118642A2 (en) * | 2004-06-01 | 2005-12-15 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
WO2006059110A2 (en) * | 2004-12-02 | 2006-06-08 | Domantis Limited | Plad domain peptides with increased serum half life due to conjugation to domain antibodies |
WO2008052933A2 (en) * | 2006-10-30 | 2008-05-08 | Domantis Limited | Prevention of aggregation of immunoglobulin light or heavy chains |
Family Cites Families (202)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US700598A (en) | 1901-03-21 | 1902-05-20 | Le Carbone Sa | Primary battery. |
CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
EP0467416A1 (en) | 1983-09-01 | 1992-01-22 | Hybritech Incorporated | Antibody compositions of therapeutic agents having an extended serum half-life |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5120712A (en) * | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
SU1441787A1 (ru) | 1987-04-29 | 1990-09-23 | Институт Белка Ан Ссср | Способ получени пептидов и белков в бесклеточной системе трансл ции |
DE3853515T3 (de) | 1987-05-21 | 2005-08-25 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
EP0298654B1 (en) | 1987-07-07 | 1994-06-01 | Hybrisens Ltd. | Use of antibody/antigen interactions to protect or modulate biological activity |
JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5225540A (en) | 1988-04-26 | 1993-07-06 | Du Pont Merck Pharmaceutical Company | Monoclonal antibodies to tissue plasminogen activator (t-pa) which prolong its functional half-life |
AU4128089A (en) * | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
ATE102631T1 (de) | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
AU649217B2 (en) | 1988-11-18 | 1994-05-19 | Regents Of The University Of California, The | Method for site-specifically incorporating unnatural amino acids into proteins |
SU1705302A1 (ru) | 1988-12-22 | 1992-01-15 | Институт Белка Ан Ссср | Способ препаративной экспрессии генов в бесклеточной системе сопр женной транскрипции/трансл ции |
CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
DE69029744T2 (de) | 1989-07-31 | 1997-07-10 | Inst Of Protein Research Russi | Verfahren zur herstellung von polypeptiden in einem zellfreien system |
SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
WO1991002078A1 (en) | 1989-08-07 | 1991-02-21 | Peptide Technology Ltd | Tumour necrosis factor binding ligands |
US6498237B2 (en) * | 1989-08-07 | 2002-12-24 | Peptech Limited | Tumor necrosis factor antibodies |
US5977307A (en) | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
DK0494955T3 (da) | 1989-10-05 | 1998-10-26 | Optein Inc | Cellefri syntese og isolering af hidtil ukendte gener og polypeptider |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5459061A (en) * | 1990-01-26 | 1995-10-17 | W. Alton Jones Cell Science Center, Inc. | Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
WO1991018980A1 (en) | 1990-06-01 | 1991-12-12 | Cetus Corporation | Compositions and methods for identifying biologically active molecules |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
GB9016299D0 (en) | 1990-07-25 | 1990-09-12 | Brien Caroline J O | Binding substances |
AU8498091A (en) | 1990-08-02 | 1992-03-02 | Regents Of The University Of Colorado, The | Systematic polypeptide evolution by reverse translation |
US5843701A (en) | 1990-08-02 | 1998-12-01 | Nexstar Pharmaceticals, Inc. | Systematic polypeptide evolution by reverse translation |
WO1992005258A1 (en) | 1990-09-20 | 1992-04-02 | La Trobe University | Gene encoding barley enzyme |
US5726152A (en) * | 1990-09-21 | 1998-03-10 | Merck & Co., Inc. | Vascular endothelial cell growth factor II |
EP0572529A4 (en) | 1991-02-21 | 1994-11-02 | Gilead Sciences Inc | SPECIFIC APTAMER OF BIOMOLECULES AND PROCESS FOR PRODUCING THE SAME. |
US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
ES2194838T3 (es) | 1991-02-27 | 2003-12-01 | Micromet Ag | Enlazadores peptidicos ricos en serina. |
DK0531472T3 (da) * | 1991-03-06 | 2003-12-01 | Merck Patent Gmbh | Humaniserede monoklonale antistoffer |
OA10149A (en) * | 1991-03-29 | 1996-12-18 | Genentech Inc | Vascular endothelial cell growth factor antagonists |
US6582959B2 (en) * | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
WO1993000917A1 (en) * | 1991-07-05 | 1993-01-21 | Seragen, Inc. | Epidermal growth factor receptor targeted molecules for treatment of inflammatory arthritis |
DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
DE69233782D1 (de) | 1991-12-02 | 2010-05-20 | Medical Res Council | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
US5965132A (en) * | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
ES2338791T3 (es) | 1992-08-21 | 2010-05-12 | Vrije Universiteit Brussel | Inmunoglobulinas desprovistas de cadenas ligeras. |
CA2150262C (en) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
HU225496B1 (en) | 1993-04-07 | 2007-01-29 | Scios Inc | Pharmaceutical compositions of prolonged delivery, containing peptides |
US5426039A (en) | 1993-09-08 | 1995-06-20 | Bio-Rad Laboratories, Inc. | Direct molecular cloning of primer extended DNA containing an alkane diol |
WO1995011922A1 (en) | 1993-10-29 | 1995-05-04 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
IL112372A (en) * | 1994-02-07 | 2001-08-26 | Res Dev Foundation | Non-viral vector for the delivery of genetic information to cells |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
GB9410533D0 (en) * | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | In situ hybridisation and immuno-Chemical localisation of a growth factor |
GB9416721D0 (en) | 1994-08-18 | 1994-10-12 | Short Brothers Plc | A bias yarn assembly forming device |
DE69523857T2 (de) * | 1994-09-16 | 2002-06-13 | Merck Patent Gmbh | Immunokonjugate |
US5573957A (en) | 1994-09-28 | 1996-11-12 | Spectral Diagnostics, Inc. | Monoclonal antibody to human cardiac myoglobin |
US5712381A (en) | 1994-10-19 | 1998-01-27 | Genetics Institute, Inc. | MADD, a TNF receptor death domain ligand protein |
US5928939A (en) * | 1995-03-01 | 1999-07-27 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-b and dna coding therefor |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
US6410690B1 (en) * | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
EP0753551B1 (en) | 1995-07-11 | 2000-02-09 | E.I. Du Pont De Nemours And Company | Ink set and process for alleviating bleed in printed elements |
PT859841E (pt) | 1995-08-18 | 2002-11-29 | Morphosys Ag | Bibliotecas de proteinas/ (poli) peptidos |
US6020473A (en) * | 1995-08-25 | 2000-02-01 | Genentech, Inc. | Nucleic acids encoding variants of vascular endothelial cell growth factor |
US5989830A (en) * | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
US6096548A (en) | 1996-03-25 | 2000-08-01 | Maxygen, Inc. | Method for directing evolution of a virus |
US5664034A (en) * | 1996-05-21 | 1997-09-02 | Lucent Technologies Inc. | Lightwave communication monitoring switch |
US5922845A (en) * | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
US6013780A (en) * | 1996-09-06 | 2000-01-11 | Technion Research & Development Co. Ltd. | VEGF145 expression vectors |
US6750044B1 (en) * | 1996-10-17 | 2004-06-15 | Genentech, Inc. | Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
EP2261373A3 (en) | 1997-01-17 | 2011-12-14 | Codexis Mayflower Holdings, LLC | Evolution of whole cells and organisms by recursive sequence recombination |
US6326204B1 (en) | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
EP0971946B1 (en) | 1997-01-21 | 2006-07-05 | The General Hospital Corporation | Selection of proteins using rna-protein fusions |
US20030165467A1 (en) * | 1997-01-21 | 2003-09-04 | Technion Research & Development Co., Ltd. | Angiogenic factor and use thereof in treating cardiovascular disease |
US6294170B1 (en) * | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
US6485942B1 (en) * | 1997-02-14 | 2002-11-26 | Genentech, Inc. | Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production |
AUPO561697A0 (en) | 1997-03-13 | 1997-04-10 | Crc For Cardiac Technology | Haemocompatible surfaces |
NZ337900A (en) | 1997-03-18 | 2001-05-25 | Novo Nordisk As | DNA shuffling for randomised heterologous and homogenous 3' and 5' primers for construction of DNA libraries for generation of more desirable mutants |
JP4263248B2 (ja) | 1997-03-18 | 2009-05-13 | ノボザイムス アクティーゼルスカブ | Dnaのシャッフリングによるライブラリーの作成方法 |
US5948653A (en) | 1997-03-21 | 1999-09-07 | Pati; Sushma | Sequence alterations using homologous recombination |
US6153410A (en) | 1997-03-25 | 2000-11-28 | California Institute Of Technology | Recombination of polynucleotide sequences using random or defined primers |
US20020032315A1 (en) * | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
CA2288992C (en) | 1997-04-30 | 2012-06-12 | Enzon, Inc. | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof |
US20020173629A1 (en) * | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
CA2292415A1 (en) | 1997-06-20 | 1998-12-30 | Innogenetics N.V. | B7-binding molecules for treating immune diseases |
CA2792122C (en) | 1997-07-07 | 2015-09-08 | Medical Research Council | In vitro sorting method |
WO1999005163A1 (en) | 1997-07-24 | 1999-02-04 | Medical Research Council | Refolding method using a foldase and a chaperone |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
CN1203178C (zh) | 1997-10-27 | 2005-05-25 | 尤尼利弗公司 | 多价抗原结合蛋白 |
US6399383B1 (en) | 1997-10-28 | 2002-06-04 | Maxygen, Inc. | Human papilloma virus vectors |
US6596539B1 (en) | 1997-10-31 | 2003-07-22 | Maxygen, Inc. | Modification of virus tropism and host range by viral genome shuffling |
EP2270234B1 (en) | 1997-12-08 | 2013-03-06 | California Institute of Technology | Method for creating polynucleotide and polypeptide sequences |
US6777534B1 (en) * | 1997-12-09 | 2004-08-17 | Children's Medical Center Corporation | Peptide antagonists of vascular endothelial growth factor |
DE69922159T2 (de) | 1998-01-23 | 2005-12-01 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Mehrzweck-antikörperderivate |
WO1999041383A1 (en) | 1998-02-11 | 1999-08-19 | Maxygen, Inc. | Antigen library immunization |
JP2002503461A (ja) | 1998-02-11 | 2002-02-05 | マキシジェン, インコーポレイテッド | 遺伝子ワクチンベクター工学 |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
US20020192211A1 (en) * | 1998-03-17 | 2002-12-19 | Hudziak Robert M. | Method of treating tumor cells by inhibiting growth factor receptor function |
US20030224001A1 (en) * | 1998-03-19 | 2003-12-04 | Goldstein Neil I. | Antibody and antibody fragments for inhibiting the growth of tumors |
ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
US20030175271A1 (en) * | 1998-05-20 | 2003-09-18 | Kyowa Hakko Kogyo Co., Ltd. | VEGF activity inhibitor |
WO2000000632A1 (en) | 1998-06-29 | 2000-01-06 | Phylos, Inc. | Methods for generating highly diverse libraries |
US20020172678A1 (en) * | 2000-06-23 | 2002-11-21 | Napoleone Ferrara | EG-VEGF nucleic acids and polypeptides and methods of use |
US7264801B2 (en) * | 1998-08-11 | 2007-09-04 | Genentech, Inc. | EG-VEGF nucleic acids and polypeptides and method of use |
FR2782323B1 (fr) | 1998-08-12 | 2002-01-11 | Proteus | Procede de production in vitro de sequences polynucleotidiques recombinees, banques de sequences et sequences ainsi obtenues |
NZ527053A (en) | 1998-09-24 | 2005-04-29 | Upjohn Co | Modified amyloid precursor protein polynucleotides and polypeptides |
KR20010085850A (ko) | 1998-09-29 | 2001-09-07 | 추후제출 | 코돈 변형 유전자의 재편성 |
US7488590B2 (en) * | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
EP1002861A1 (en) | 1998-10-26 | 2000-05-24 | Unilever Plc | Antigen-binding proteins comprising a linker which confers restricted conformational flexibility |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
DK1137812T3 (da) | 1998-12-02 | 2007-05-21 | Adnexus Therapeutics Inc | DNA-proteinfusioner og anvendelser deraf |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
DK1140173T4 (da) * | 1998-12-22 | 2013-06-10 | Genentech Inc | Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf |
GB9900298D0 (en) | 1999-01-07 | 1999-02-24 | Medical Res Council | Optical sorting method |
WO2000042559A1 (en) | 1999-01-18 | 2000-07-20 | Maxygen, Inc. | Methods of populating data structures for use in evolutionary simulations |
US6436675B1 (en) | 1999-09-28 | 2002-08-20 | Maxygen, Inc. | Use of codon-varied oligonucleotide synthesis for synthetic shuffling |
AU3210100A (en) | 1999-01-19 | 2000-08-01 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
AU4499499A (en) | 1999-04-01 | 2000-10-23 | Innogenetics N.V. | A polypeptide structure for use as a scaffold |
SE9901379D0 (sv) | 1999-04-19 | 1999-04-19 | Pharmacia & Upjohn Ab | Receptor structures |
US6703020B1 (en) * | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
IL145941A (en) * | 1999-04-28 | 2007-08-19 | Univ Texas | Preparations and methods for the treatment of cancer by selective inhibition of VEGF |
US7049410B2 (en) * | 1999-05-14 | 2006-05-23 | Majumdar Adhip P N | Antibodies to a novel EGF-receptor related protein (ERRP) |
KR20020000223A (ko) * | 1999-05-14 | 2002-01-05 | 존 비. 랜디스 | 표피성장인자 수용체 길항제를 사용한 인간 난치성 종양의치료 방법 |
CA2372198A1 (en) | 1999-05-14 | 2000-11-23 | Medical Research Council | Protein scaffold and its use to multimerise monomeric polypeptides |
JP2003507006A (ja) * | 1999-05-20 | 2003-02-25 | サイオス,インコーポレーテッド | 血管内皮増殖因子改変体 |
US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
EP2180054A1 (en) | 1999-12-24 | 2010-04-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
WO2001058953A2 (en) | 2000-02-11 | 2001-08-16 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function |
WO2001062942A2 (en) * | 2000-02-25 | 2001-08-30 | Ludwig Institute For Cancer Research | MATERIALS AND METHODS INVOLVING HYBRID VASCULAR ENDOTHELIAL GROWTH FACTOR DNAs AND PROTEINS AND SCREENING METHODS FOR MODULATORS |
EP1268544A2 (en) * | 2000-03-31 | 2003-01-02 | Institut Pasteur | Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof |
IL151853A0 (en) * | 2000-04-11 | 2003-04-10 | Genentech Inc | Multivalent antibodies and uses therefor |
AU2001264920A1 (en) * | 2000-05-22 | 2001-12-03 | Ho, Alice, Suk-Yue | Therapeutic uses of il-1 receptor antagonist |
US20020103345A1 (en) * | 2000-05-24 | 2002-08-01 | Zhenping Zhu | Bispecific immunoglobulin-like antigen binding proteins and method of production |
GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
KR20080074231A (ko) | 2000-06-29 | 2008-08-12 | 아보트 러보러터리즈 | 이중 특이성 항체 및 이의 제조 및 사용 방법 |
DE10038624C2 (de) * | 2000-08-03 | 2002-11-21 | Broekelmann Aluminium F W | Wärmeübertragungsrohr mit gedrallten Innenrippen |
US6699473B2 (en) * | 2000-10-13 | 2004-03-02 | Uab Research Foundation | Human anti-epidermal growth factor receptor single-chain antibodies |
KR20080085082A (ko) | 2000-12-07 | 2008-09-22 | 일라이 릴리 앤드 캄파니 | Glp-1 융합 단백질 |
WO2002051870A2 (en) | 2000-12-22 | 2002-07-04 | GRAD, Carole Legal Representative of KAPLAN, Howard | Phage display libraries of human vh fragments |
US7054297B1 (en) | 2000-12-28 | 2006-05-30 | Cisco Technology, Inc. | Distribution of packets to high data rate communications devices using multicast protocols |
US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
EP1455820A2 (en) | 2001-03-09 | 2004-09-15 | William Herman | Targeted ligands |
CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
US7667004B2 (en) * | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
JP4369662B2 (ja) | 2001-04-26 | 2009-11-25 | アビディア インコーポレイテッド | 単量体ドメインのコンビナトリアルライブラリー |
US20050048512A1 (en) | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
CN1507355A (zh) * | 2001-05-08 | 2004-06-23 | Ĭ��ר������˾ | 使用抗egfr抗体和抗激素剂的联合疗法 |
US7247301B2 (en) * | 2001-06-13 | 2007-07-24 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
DE60237282D1 (de) | 2001-06-28 | 2010-09-23 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
CA2456236A1 (en) * | 2001-08-03 | 2003-02-20 | Commonwealth Scientific And Industrial Research Organisation | Methods of screening based on the egf receptor crystal structure |
IL160983A0 (en) | 2001-09-24 | 2004-08-31 | Imp College Innovations Ltd | Use of pyy for preparation of a medicament for modification of feeding behavior |
EP1448780A4 (en) * | 2001-10-15 | 2005-08-31 | Immunomedics Inc | DIRECTLY TARGETED BONDING PROTEINS |
JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
CA2468583C (en) | 2001-11-30 | 2012-05-01 | C. Roger Mackenzie | Self-assembling multimeric binding complexes derived from ab5 toxin family members |
DE10163459A1 (de) * | 2001-12-21 | 2003-07-03 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor |
EP1474163A2 (en) | 2002-01-10 | 2004-11-10 | Imperial College Innovations Limited | Modification of feeding behavior |
WO2003074569A2 (en) * | 2002-03-01 | 2003-09-12 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
EP1576172A2 (en) | 2002-06-21 | 2005-09-21 | Dyax Corporation | Serum protein-associated target-specific ligands and identification method therefor |
US7696320B2 (en) * | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
DK2213685T3 (en) * | 2002-09-06 | 2014-03-03 | Medarex Llc | Therapeutic anti-IL-1R1 monoclonal antibody |
TW200501960A (en) * | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
JP5179702B2 (ja) | 2002-10-10 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 受容体Erb−B1に対する医薬組成物 |
US20060228355A1 (en) | 2003-11-07 | 2006-10-12 | Toon Laeremans | Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor |
EP2284192A3 (en) | 2002-11-08 | 2011-07-20 | Ablynx N.V. | Camelidae antibodies for sublingual administration |
EP1578801A2 (en) | 2002-12-27 | 2005-09-28 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
MXPA05006043A (es) | 2003-01-10 | 2006-01-30 | Ablynx Nv | Polipeptidos terapeuticos, homologos de los mismos, fragmentos de los mismos y para uso al modular la agregacion mediada de plaquetas. |
EP1592777A4 (en) | 2003-02-01 | 2008-06-04 | Tanox Inc | METHOD OF GENERATING HIGH-ANTIBODY ANTIBODIES |
US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
WO2004101790A1 (en) | 2003-05-14 | 2004-11-25 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
UA101945C2 (ru) * | 2003-05-30 | 2013-05-27 | Дженентек, Инк. | Лечение злокачественного новообразования с помощью бевацизумаба |
AU2004247095A1 (en) * | 2003-06-06 | 2004-12-23 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for tumor regression |
CA2530172A1 (en) * | 2003-06-27 | 2005-02-10 | Abgenix, Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
EP2221317A3 (en) | 2003-06-30 | 2011-07-27 | Domantis Limited | PEGylated single domain antibodies (dAb) |
AR046510A1 (es) * | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
US20050196340A1 (en) * | 2003-08-06 | 2005-09-08 | Jocelyn Holash | Use of a VEGF antagonist in combination with radiation therapy |
CA2534898A1 (en) * | 2003-08-08 | 2005-02-17 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
WO2005040229A2 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
US20050226863A1 (en) | 2003-11-20 | 2005-10-13 | Massachusetts Institute Of Technology | Single-domain antibodies and uses thereof |
AU2005206536B2 (en) * | 2004-01-16 | 2010-09-02 | Regeneron Pharmaceuticals, Inc. | Fusion polypeptides capable of activating receptors |
US7767792B2 (en) * | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
MX2007000105A (es) | 2004-07-06 | 2007-07-18 | Bioren Inc | Mutagenesis look-through para crear polipeptidos alterados con propiedades mejoradas. |
US7180370B2 (en) | 2004-09-01 | 2007-02-20 | Micron Technology, Inc. | CMOS amplifiers with frequency compensating capacitors |
KR20070084069A (ko) | 2004-10-08 | 2007-08-24 | 도만티스 리미티드 | Tnfr1에 대한 단일 도메인 항체 및 이의 사용 방법 |
US20090214534A1 (en) * | 2004-12-02 | 2009-08-27 | Steve Holmes | Bispecific Domain Antibodies Targeting Serum Albumin And GLP-1 Or PYY |
WO2006059108A2 (en) * | 2004-12-02 | 2006-06-08 | Domantis Limited | ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES |
DK1888641T3 (da) | 2005-05-18 | 2012-04-23 | Ablynx Nv | Serumalbuminbindende proteiner |
BRPI0619463A2 (pt) * | 2005-12-06 | 2013-01-08 | Domantis Ltd | ligando, uso do mesmo, mÉtodos para tratar cÂncer e para administrar um tratamento anti-vegf e tratamento anti-egfr a um indivÍduo, composiÇço, dispositivo de dispensaÇço de droga, Ácido nucleico isolado ou recombinante, vetor, cÉlula hospedeira, mÉtodo para produzir um ligando, polipeptÍdeo de domÍnio variÁvel simples de imunoglobulina, e, antagonista de egfr |
-
2007
- 2007-02-08 US US11/704,832 patent/US9321832B2/en active Active
-
2008
- 2008-02-08 AR ARP080100543A patent/AR065260A1/es not_active Application Discontinuation
- 2008-02-08 ES ES12168402.1T patent/ES2629353T3/es active Active
- 2008-02-08 SG SG2012009023A patent/SG185869A1/en unknown
- 2008-02-08 MX MX2009008490A patent/MX2009008490A/es active IP Right Grant
- 2008-02-08 EA EA200900955A patent/EA020464B9/ru not_active IP Right Cessation
- 2008-02-08 JP JP2009548740A patent/JP5562650B2/ja not_active Expired - Fee Related
- 2008-02-08 CA CA002677069A patent/CA2677069A1/en not_active Abandoned
- 2008-02-08 KR KR1020097018763A patent/KR20090114445A/ko active Application Filing
- 2008-02-08 CN CN2008800104821A patent/CN101965364A/zh active Pending
- 2008-02-08 EP EP12168402.1A patent/EP2559702B1/en active Active
- 2008-02-08 KR KR1020147036166A patent/KR20150014995A/ko not_active Application Discontinuation
- 2008-02-08 BR BRPI0807480-1A2A patent/BRPI0807480A2/pt not_active IP Right Cessation
- 2008-02-08 EP EP08702087.1A patent/EP2139918B1/en active Active
- 2008-02-08 WO PCT/GB2008/000453 patent/WO2008096158A2/en active Application Filing
- 2008-02-08 EP EP12168404A patent/EP2559704A1/en not_active Withdrawn
- 2008-02-08 AU AU2008212682A patent/AU2008212682B2/en not_active Ceased
- 2008-02-08 EP EP12168403A patent/EP2559703A1/en not_active Withdrawn
- 2008-02-08 CL CL200800423A patent/CL2008000423A1/es unknown
- 2008-02-08 ES ES08702087.1T patent/ES2629333T3/es active Active
- 2008-02-12 TW TW097104963A patent/TW200848427A/zh unknown
-
2014
- 2014-04-22 JP JP2014088162A patent/JP2014193869A/ja active Pending
-
2015
- 2015-10-28 US US14/924,971 patent/US20170145080A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004003019A2 (en) * | 2002-06-28 | 2004-01-08 | Domantis Limited | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
WO2005118642A2 (en) * | 2004-06-01 | 2005-12-15 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
WO2006059110A2 (en) * | 2004-12-02 | 2006-06-08 | Domantis Limited | Plad domain peptides with increased serum half life due to conjugation to domain antibodies |
WO2008052933A2 (en) * | 2006-10-30 | 2008-05-08 | Domantis Limited | Prevention of aggregation of immunoglobulin light or heavy chains |
Also Published As
Publication number | Publication date |
---|---|
SG185869A1 (en) | 2012-12-28 |
EA020464B1 (ru) | 2014-11-28 |
WO2008096158A3 (en) | 2008-12-18 |
CA2677069A1 (en) | 2008-08-14 |
EA200900955A1 (ru) | 2010-04-30 |
AU2008212682B2 (en) | 2013-09-26 |
ES2629353T3 (es) | 2017-08-08 |
US9321832B2 (en) | 2016-04-26 |
BRPI0807480A2 (pt) | 2014-05-06 |
EP2559703A1 (en) | 2013-02-20 |
CL2008000423A1 (es) | 2008-10-24 |
CN101965364A (zh) | 2011-02-02 |
JP2014193869A (ja) | 2014-10-09 |
EP2559702B1 (en) | 2017-04-19 |
EP2139918A2 (en) | 2010-01-06 |
AR065260A1 (es) | 2009-05-27 |
MX2009008490A (es) | 2010-01-15 |
KR20150014995A (ko) | 2015-02-09 |
WO2008096158A8 (en) | 2009-10-15 |
AU2008212682A1 (en) | 2008-08-14 |
TW200848427A (en) | 2008-12-16 |
WO2008096158A2 (en) | 2008-08-14 |
EP2559704A1 (en) | 2013-02-20 |
EP2559702A1 (en) | 2013-02-20 |
KR20090114445A (ko) | 2009-11-03 |
US20170145080A1 (en) | 2017-05-25 |
JP2010518062A (ja) | 2010-05-27 |
ES2629333T3 (es) | 2017-08-08 |
EP2139918B1 (en) | 2017-04-19 |
US20090259026A1 (en) | 2009-10-15 |
JP5562650B2 (ja) | 2014-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA020464B9 (ru) | Отдельные вариабельные домены антител против сывороточного альбумина | |
WO2004003019A3 (en) | Immunoglobin single variant antigen-binding domains and dual-specific constructs | |
DE60237282D1 (de) | Doppelspezifischer ligand und dessen verwendung | |
WO2009058383A3 (en) | Ligand | |
WO2008048970A8 (en) | Synthetic antibodies | |
WO2006130374A3 (en) | Tweak binding antibodies | |
WO2007095338A3 (en) | Functional antibodies | |
WO2009009116A3 (en) | Combination therapies employing gitr binding molecules | |
MX2008011874A (es) | Composiciones estabilizadas de polipeptidos. | |
WO2012088302A3 (en) | Half immunoglobulin binding proteins and uses thereof | |
IL183450A0 (en) | Bispecific domain antibodies targeting serum albumin and glp-1 or pyy | |
DK1751181T3 (da) | BINDINGSDELE, DER ER BASERET PÅ HAJ IgNAR-DOMÆNER | |
MX2009008656A (es) | Anticuerpos contra erbb3 y usos de los mismos. | |
WO2009140039A3 (en) | Synthetic antibodies | |
ZA200704431B (en) | Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY | |
WO2008101160A3 (en) | Htra1-pdz and htra3-pdz modulators | |
WO2008097439A3 (en) | Anti-autoimmune antibodies for treatment of pemphigus | |
WO2009055669A3 (en) | Monoclonal antibodies against activated and unactivated protein c | |
WO2007026972A3 (en) | Binding protein molecule | |
FR2865897B1 (fr) | Modulateurs de developpement des champignons mycorhiziens a arbuscules, et applications. | |
NO20090333L (no) | Fremgangsmater og preparater rettet mot hepsin | |
CY1111435T1 (el) | Διπλα-ειδικος συνδετηρας και χρηση αυτου | |
MY142617A (en) | Dual specific ligands with increased serum half-life | |
ATE411070T1 (de) | Kanülenansatzsystem | |
WO2007072022A3 (en) | Composition comprising an antigen-recognizing molecule and a lipid-based carrier |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TH4A | Publication of the corrected specification to eurasian patent | ||
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |